¼¼°èÀÇ À¯¹æ¾Ï ¾×ü »ý°Ë ½ÃÀå, ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : ¼øÈ¯ ¹ÙÀÌ¿À¸¶Ä¿º°, ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast (2025-2034)
»óǰÄÚµå : 1605803
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 116 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, À¯¹æ¾Ï ¾×ü »ý°Ë ¼¼°è ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 27¾ï 3,102¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

À¯¹æ¾Ï ¾×ü»ý°Ë ½ÃÀåÀº Àü ¼¼°è À¯¹æ¾Ï À¯º´·ü Áõ°¡¿Í ºñħ½ÀÀû Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¾×ü »ý°ËÀº Ç÷¾× »ùÇÿ¡¼­ ¼øÈ¯ Á¾¾ç DNA(ctDNA)¿Í ¼øÈ¯ Á¾¾ç ¼¼Æ÷(CTC)¸¦ ºÐ¼®ÇÕ´Ï´Ù. ±âÁ¸ Á¶Á÷ »ý°Ë¿¡ ºñÇØ ȯÀÚÀÇ ºÒÆíÇÔÀ» ÁÙÀ̰í Ä¡·á È¿°ú¸¦ ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â µî ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ºÐÀÚ»ý¹°ÇÐ ¹× À¯ÀüüÇÐÀÇ ¹ßÀüÀ¸·Î ¾×ü»ý°Ë °Ë»ç°¡ °³¼±µÇ¾î À¯¹æ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í ´õ Á¤È®ÇÏ°Ô Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¾Ï Á¶±â ¹ß°ßÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¾×ü »ý°Ë ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Ï °ËÁøÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ¿¬±¸ º¸Á¶±Ýµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀ¸·Î Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¾×ü »ý°ËÀº ȯÀÚº° À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î ȯÀÚ °³°³Àο¡°Ô ¸ÂÃãÈ­µÈ Ä¡·á¸¦ À§ÇÑ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

´ëÇü »ý¸í°øÇÐ ±â¾÷°ú Á¦¾àȸ»çÀÇ Á¸Àç¿Í Ȱ¹ßÇÑ ¿¬±¸°³¹ß Ȱµ¿Àº ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ» ´õ¿í ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ȯ°æÀÌ ¹ßÀüÇÏ°í ¾×ü »ý°Ë ±â¼úÀ» äÅÃÇÏ´Â ÀÇ·á ±â°üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾×ü »ý°ËÀº À¯¹æ¾ÏÀÇ Áø´Ü°ú °ü¸®¸¦ °³¼±Çϰí ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. À§ÀÇ ¸ðµç ¿äÀÎÀº À¯¹æ¾Ï ¾×ü »ý°Ë ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

À¯¹æ¾Ï ¾×ü »ý°Ë ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¼øÈ¯ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±âÁØÀ¸·Î 2024³â ¼øÈ¯ ¹«¼¼Æ÷ DNA(cfDNA) ºÎ¹®Àº ¹Î°¨µµ Çâ»óÀ¸·Î ÀÎÇØ À¯¹æ¾Ï ¾×ü »ý°Ë ½ÃÀå¿¡¼­ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶±â ¾Ï Áø´ÜÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â ¹ß°ß/°ËÁø ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2024³â ºÏ¹Ì°¡ À¯¹æ¾Ï ¾×ü»ý°Ë ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Âµ¥, ÀÌ´Â ºÏ¹Ì Àüü¿¡¼­ Çõ½ÅÀûÀÎ Áø´Ü ±â¼ú äÅ÷üÀÌ ³ô±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÀÌ Áö¿ª Àüü¿¡¼­ À¯¹æ¾Ï À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷À¸·Î´Â Biocept, Inc. Laboratories, QIAGEN, QIAGEN, Sysmex Corporation, The Menarini Group, Thermo Fisher Scientific, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ À¯¹æ¾Ï ¾×ü»ý°Ë ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ À¯¹æ¾Ï ¾×ü»ý°Ë ½ÃÀå : ¼øÈ¯ ¹ÙÀÌ¿À¸¶Ä¿º°

Á¦6Àå ¼¼°èÀÇ À¯¹æ¾Ï ¾×ü»ý°Ë ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°èÀÇ À¯¹æ¾Ï ¾×ü»ý°Ë ½ÃÀå : Áö¿ªº°

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global breast cancer liquid biopsy market size is expected to reach USD 2,731.02 million by 2034, according to a new study by Polaris Market Research. The report "Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report - By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The breast cancer liquid biopsy market is experiencing significant growth due to the increasing prevalence of breast cancer globally and the rising demand for noninvasive diagnostic tools. Liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples. It offers several advantages over traditional tissue biopsies, including reduced patient discomfort and the ability to monitor treatment response in real time. Advancements in molecular biology and genomics have improved liquid biopsy tests, enabling earlier detection and more precise treatment of breast cancer, further boosting market growth.

The rising awareness among healthcare professionals and patients regarding the benefits of early cancer detection is driving demand for liquid biopsy solutions. Government initiatives promoting cancer screening and research funding also play a crucial role in fostering market growth. In addition, the shift toward personalized medicine is leading to a greater emphasis on targeted therapies, making liquid biopsies an essential tool for tailoring treatments to individual patients based on their unique genetic profiles.

The presence of major biotechnology and pharmaceutical companies, coupled with robust research and development activities, is further stimulating innovation in this sector. As the healthcare landscape evolves and more providers adopt liquid biopsy technology, it improves breast cancer diagnosis and management while enhancing patient outcomes. All these factors mentioned above drive the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.

The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.

In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.

The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.

A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the breast cancer liquid biopsy market report on the basis of circulating biomarkers, application, and region:

By Circulating Biomarkers Outlook (Revenue - USD Million, 2020-2034)

By Application Outlook (Revenue - USD Million, 2020-2034)

By Regional Outlook (Revenue - USD Million, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Breast Cancer Liquid Biopsy Market Insights

5. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers

6. Global Breast Cancer Liquid Biopsy Market, by Application

7. Global Breast Cancer Liquid Biopsy Market, by Geography

8. Competitive Landscape

9. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â